General Information of Drug (ID: DMJTB4E)

Drug Name
CDP-484 Drug Info
Synonyms Anti-IL-1 beta FAb-PEG, Celltech
Indication
Disease Entry ICD 11 Status REF
Immune System disease 4A01-4B41 Discontinued in Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMJTB4E

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-1 beta (IL1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [3]
Rilonacept DMGLUQS Arthritis FA20 Approved [4]
Gallium nitrate DMF9O6B Hypercalcaemia 5B91.0 Approved [5]
Canakinumab DM8HLO5 Autosomal dominant familial periodic fever Approved [6]
Diacerein DMN2Q5I N. A. N. A. Phase 4 [7]
XOMA 052 DMOKQV7 Type-2 diabetes 5A11 Phase 3 [8]
ABT-981 DM6PTIX Osteoarthritis FA00-FA05 Phase 2 [9]
AC-201 DMB0TNL Type-2 diabetes 5A11 Phase 2 [10]
LY-2189102 DMU81BH Cardiovascular disease BA00-BE2Z Phase 2 [11]
TT-301 DM4QV8Y Alzheimer disease 8A20 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-1 beta (IL1B) TTRYK0X IL1B_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016757)
2 Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis. 2006 September; 1(3): 321-334.
3 Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98.
4 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
5 Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and revie... Med Hypotheses. 2005;65(6):1136-41.
6 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7 Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86.
8 Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010 Dec;12(6):755-69.
9 Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46.
12 A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176.